The panel is meeting and currently reviewing data to update the Guidance based on the US FDA approval of ledipasvir/sofosbuvir. The updated Guidance will be posted in early December.
What’s New and Updates/Changes
The introductory statement of When and In Whom to Initiate Therapy has been revised to reiterate that treatment will benefit almost all patients in all stages of chronic infection and that urgent initiation of therapy is needed in patients with certain conditions.
The newest section of the AASLD/IDSA/IAS-USA hepatitis C Guidance, Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy, is now available. Click here to access this section.